Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Colorcon
McKinsey
AstraZeneca
Medtronic

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

Litigation Details for King Pharmaceuticals Research and Development, Inc. v. SICOR Inc. (D. Del. 2005)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Small Molecule Drugs cited in King Pharmaceuticals Research and Development, Inc. v. SICOR Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for King Pharmaceuticals Research and Development, Inc. v. SICOR Inc. (D. Del. 2005)

Date Filed Document No. Description Snippet Link To Document
2005-05-26 1 Exhibit A .......... 600/3, 4; 128/659 c; 424/9; 514/46, 47 [56] References Cited U.S. PATENT DOCUMENTS 3,845,205…STATES PATENT AND TRADEMARK OFFICE CERTIFICATE EXTENDING PATENT TERM UNDER 35 U.S.C. § 156 PATENT NO. … United States Patent [19] Mohiuddin et al. Filed 05/26/2005 Page 1 of 9 [11] Patent Number: [45] Date…term of the patent for the period of 159 days from the original expiration date of the patent, December…COMMISSIONER OF PATENTS AND TRADEMARKS an application under 35 U.S.C. § 156 for an extension of the patent term. External link to document
2006-05-16 104 Stipulation 20- 26 and 43 of United States Patent No. 5,070,877 (“the ‘877 patent”). This admission is without …claims 1, 3-12, 17, 18, 20-26 and 43 of the ‘877 patent are invalid. SO STIPULATED: ___/s/ External link to document
2006-08-11 111 Claim Construction Chart construction of any claim terms for U.S. Patent No. 5,070,877 (“the ‘877 patent”), as no construction of any claim External link to document
2007-01-26 133 Proposed Pretrial Order Admission Case TX 1040 U.S. Patent No. 4,673,563 PX… assignee of United States Patent No. 5,070,877 patent (the “‘877 patent”). 10. Pharmaceutical…Sicor for infringement of U.S. Patent No. 5,070,877 (“the ‘877 patent”) under 35 U.S.C. § 271(e)(2), … ‘877 patent under 35 U.S.C. § 271(e)(2). 10. This action arises under the patent laws of…”). II. THE ‘877 PATENT 6. The United States Patent and Trademark Office (“PTO External link to document
2007-05-09 143 POST Trial Brief claims of United States Patent No. 5,070,877 (the “‘877 patent”). The ‘877 patent claims nothing more than…-in-part patent application that led to United States Patent No. 5,731,296 (the “‘296 patent”) described…of the ‘877 patent are neither novel nor non-obvious. Accordingly, they are not patentable and should …invention is not patentable “if the differences between the subject matter sought to be patented and the prior… the relevant field of art of the ‘877 patent. The ‘877 patent concerns the use of vasodilators as pharmacological External link to document
2007-05-09 146 Proposed Findings of Fact exclusive licensee of rights under U.S. Patent No. 5,731,296 (the ‘296 patent), which is owned by Item Development…infringement of King’s United States Patent No. 5,070,877 (“the ‘877 patent”). (D.I. 1 ¶¶ 30-31.) …). The ‘877 patent is now assigned to King. (D.I 133, Ex. 1, ¶¶ 6-7, 9.) The ‘877 patent claims generally…product would not infringe the ‘877 patent and/or (ii) the ‘877 patent was invalid or unenforceable. (TX…the ‘877 patent. However, Sicor subsequently amended its ANDA to certify that the ‘877 patent was invalid External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Merck
Express Scripts
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.